Literature DB >> 10648634

beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue.

A A Konkar1, Y Zhai, J G Granneman.   

Abstract

CGP 12177 is a beta-adrenergic receptor (AR) ligand that has been used to characterize the beta3-AR and the putative beta4-AR. The ability of CGP 12177 to activate beta1-AR when overexpressed in vitro and the presence of beta1-AR in tissues expressing putative beta4-AR prompted us to investigate the actions of CGP 12177 at recombinant and natively-expressed beta-AR. CGP 12177 potently activated recombinant rat and human beta1-AR expressed in Chinese hamster ovary cells. This activation, like that of putative beta4-AR, was resistant to blockade by selective and nonselective beta-AR antagonists. Brown fat has been proposed to contain beta4-AR, as evidenced by the presence of CGP 12177-mediated thermogenesis in mice lacking beta3-AR. Therefore, the identity of the receptors mediating CGP 12177 responses in brown fat was examined using wild-type mice and mice lacking beta1-AR or beta3-AR. In wild-type mice, CGP 12177 activated adenylyl cyclase via high- and low-affinity sites. The high-affinity site, but not the low-affinity site, was blocked by CGP 20712 with potency indicating an interaction with beta1-AR. Moreover, the high-affinity site was absent in mice lacking beta1-AR. In contrast, the low-affinity, CGP 20712-resistant activation by CGP 12177 was absent in mice lacking beta3-AR. Rather, activation occurred exclusively through the high-affinity, CGP 20712-sensitive site. These data indicate that the actions of CGP 12177 in brown fat that have been attributed to novel beta-AR (i.e., beta4-AR) are mediated via an atypical interaction with beta1-AR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648634

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  Cellular origins of cold-induced brown adipocytes in adult mice.

Authors:  Yun-Hee Lee; Anelia P Petkova; Anish A Konkar; James G Granneman
Journal:  FASEB J       Date:  2014-11-12       Impact factor: 5.191

Review 2.  Old and new determinants in the regulation of energy expenditure.

Authors:  A P Russell; J P Giacobino
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

Review 3.  The 'state' of beta-adrenoceptors.

Authors:  Peter Molenaar
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

4.  Positive inotropic and lusitropic effects mediated via the low-affinity state of beta1-adrenoceptors in pithed rats.

Authors:  Agnieszka Zakrzeska; Eberhard Schlicker; Grzegorz Kwolek; Hanna Kozłowska; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

5.  Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?

Authors:  Jonathan R S Arch
Journal:  Br J Pharmacol       Date:  2004-11       Impact factor: 8.739

6.  Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium.

Authors:  Martin D Lowe; James A Lynham; Andrew A Grace; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

Authors:  I Muramatsu; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; M C Rodrigo; B E Myagmar; P C Simpson
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

8.  Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

9.  Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the beta1-adrenoceptor.

Authors:  Shirin S Joseph; William H Colledge; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-18       Impact factor: 3.000

10.  A study of antagonist affinities for the human histamine H2 receptor.

Authors:  J G Baker
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.